Status:
COMPLETED
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
Lead Sponsor:
Ophthotech Corporation
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degener...
Eligibility Criteria
Inclusion
- Active subfoveal NVAMD
Exclusion
- History or evidence of severe cardiac disease
- Any major surgical procedure within one month of trial entry
- Subjects with a clinically significant laboratory value
- Any treatment with an investigational agent in the past 60 days for any condition
- Women who are pregnant or nursing
- Known serious allergies to the fluorescein dye used in angiography, povidone iodine, to the components of the ranibizumab formulation, or to the components of the Zimura formulation
- Any prior treatment for AMD other than oral supplements of vitamins and minerals
Key Trial Info
Start Date :
October 11 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 18 2018
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03362190
Start Date
October 11 2017
End Date
October 18 2018
Last Update
June 10 2025
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Retinal Research Institute
Phoenix, Arizona, United States, 85053
2
Retina Centers PC
Tucson, Arizona, United States, 85704
3
Retina Associates SW, PC
Tucson, Arizona, United States, 85710
4
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211